Previous 10 | Next 10 |
We highlight the promising aspects of the AGEN story. We touch upon certain catalysts in the foreseeable future. We conclude with some technical analysis of the AGEN stock. Company Snapshot Agenus, Inc. ( AGEN ), is a clinical-stage biotech firm that is attem...
The clinical-stage immuno-oncology company, Agenus ( NASDAQ: AGEN ) jumped more than 20% on Tuesday to record the best intraday rise since May 2021 on above average volumes. More than 5.4M Agenus ( AGEN ) shares have changed hands so far, compared to the 65-day ave...
Agenus was looking at a disaster last year after it pulled its BLA. However, after reporting strong early data from 1181, it looks to be on a much more solid footing. Current lows and cash balance make it very interesting. Agenus ( AGEN ) had a disruptive 2021, when ...
LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will ...
Shares of Agenus (NASDAQ: AGEN) were soaring 27.7% higher as of 10:48 a.m. ET on Wednesday. The big gain came after the company announced results from a phase 1b study evaluating a combination of botensilimab and balstilimab in treating microsatellite-stable colorectal cancer (MSS C...
The shares of Agenus ( NASDAQ: AGEN ) surged ~24% in the morning hours Wednesday after the immuno-oncology company announced early-stage data for tumor candidates botensilimab and balstilimab in patients with a form of colorectal cancer. The Phase 1b study was designed t...
Gainers: Allena Pharmaceuticals ( ALNA ) +238% . Trevi Therapeutics TRVI +29% . Bellerophon Therapeutics ( BLPH ) +22% . Agenus ( AGEN ) +21% . Catalyst Biosciences CBIO +18% . Losers: Agile Therapeutics ( AGRX ) -29% . ...
Trevi Therapeutics ( TRVI ) +36% reports positive results from the Ph2b/3 PRISM trial of Haduvio in the treatment of Prurigo nodularis. Catalyst Biosciences CBIO +26% plans to distribute $65M cash to stockholders. 2U TWOU +18% as Byju's reportedly mak...
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4 prior lines of therapy Responses to botensilimab/balstilimab were durable, with 80% ongoing at data cut-off and median duration of response not reached Global, randomi...
iNKT cells have unique properties that could be therapeutic. MiNK Therapeutics has shown it can both manufacture and engineer iNKT cells. Preliminary data expected before year-end could push the stock price substantially higher. For further details see: MiNK Therapeutics...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...